English | Español
English | Español
  • Insurance
  • Marketing
  • Pharmaceuticals
  • Technology/Innovation
  • Regulatory
  • Community
Press release submission | Apr 25, 2019

PROVENTION BIO, INC.: Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease

Press release submission | Apr 23, 2019

ELI LILLY AND COMPANY: Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis

Press release submission | Apr 19, 2019

TELA BIO, INC.: Announces 510(k) Clearance for Restella™ Reconstructive BioScaffolds for Reconstructive Surgery

Press release submission | Apr 15, 2019

MESOTHELIOMA COMPENSATION CENTER: Now Offers to Make Certain That a Nuclear Power Worker with Mesothelioma or Asbestos Exposure Lung Cancer Gets Accelerated Compensation with The Help of Attorney Erik Karst and His Colleagues at Karst von Oiste

Press release submission | Apr 11, 2019

BD: Unveils Platelet Quality Control Media to Help Reduce the Incidence of Sepsis in Patients Requiring Platelet Transfusion

Press release submission | Apr 10, 2019

TREMOTYX BIOMEDICAL LAB: Debuts Plant Stem Cell-Based Eczema Treatment in the U.S.

Press release submission | Apr 4, 2019

VARIAN MEDICAL SYSTEM: Discloses First Preclinical Results of Potential Major Breakthrough in Cancer Treatment

Press release submission | Apr 4, 2019

GENOME MEDICAL: Renown Health and Genome Medical Partner to Bring Genetic Counseling and Educational Services to Patients for End-to-End Genetic Testing Support

Trending

Patient Daily | Jul 8, 2025

Clinical assistant professor at Stanford: ‘Musical background is associated with better performance of fundamental surgical skills'

+ Pharmaceuticals
Patient Daily | Jul 10, 2025

PhRMA Executive VP: ‘State policymakers can lead the way and must address 340B abuse and protect patients from PBMs'

+ Pharmaceuticals
Patient Daily | Jul 8, 2025

Psychedelic mushrooms' compound shows potential antiaging effects

Patient Daily | Jul 9, 2025

FDA approves Longeveron's Phase 2 study for pediatric dilated cardiomyopathy treatment

  • « First
  • «
  • …
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • …
  • »
  • Last »


Community
Insurance
Marketing
Pharmaceuticals
Regulatory
Technology/Innovation
About
Contact
© 2025 Patient Daily